RCS - Genflow Biosciences - 2024 Highlights

Genflow BiosciencesAnnouncement

06/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250106:nRSF1493Sa&default-theme=true

RNS Number : 1493S  Genflow Biosciences PLC  06 January 2025

6 January 2025

 

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

A Look Back at an Exciting 2024

 

 

2024 has been an incredible year for Genflow as we advance our mission to
develop novel therapeutics that promote a longer, healthier life.

 

Our focus on the SIRT6 gene and its potential to slow aging and delay
age-related diseases has seen significant progress. This year, we've
strengthened our leadership by collaborating with world-class researchers and
laboratories, with generous support from the Belgian Government that has been
instrumental in advancing our work.

 

Program Highlights

 

Throughout the year, our programs made significant strides, including:

 

●    MASH (GF-1002): We are advancing to the pre-IND phase of our
preclinical development and have partnered with Exothera SA for GMP
manufacturing of the clinical lot. Exothera, a specialized CDMO, provides
end-to-end GMP manufacturing services for viral vectors, RNA therapeutics and
vaccines, with state-of-the-art facilities in Belgium and the US.

 

Leveraging these innovative technologies and expertise, we are positioned to
fast-track our progress and initiate the first proof-of-concept study of our
gene therapy in patients with MASH. This milestone is a critical achievement
for the Company, signaling our readiness to transition into clinical trials
and showcasing the maturity and scalability of our therapeutic platform. Prior
to commencing GMP manufacturing, we will ensure full regulatory compliance to
reinforce confidence in our program among potential partners, investors, and
regulatory agencies.

 

●    Werner Syndrome (GF-1003): We have developed a proprietary liver
organoid derived from human cells of patients with Werner syndrome. Organoids
are miniature, three-dimensional tissue models (grown in the lab) that mimic
the structure and function of real organs.

 

Compared to using animal models, organoids offer several advantages: they are
derived from human cells from patients affected with the disease, providing
more accurate insights into human-specific biology; they reduce reliance on
animals in research; and they allow for personalized disease modeling and drug
testing tailored to individual patients.

 

●    Dog Aging (GF-1004): We are initiating a life extension clinical
trial for aging dogs in collaboration with our contract research partner,
Syngene. This six-month study will assess the potential of a veterinary
version of our gene therapy to extend both the health span and lifespan of
dogs. We expect to complete the full analysis of the trial by the end of 2025.
Based on the outcomes, we may explore partnership opportunities or licensing
agreements with veterinary specialty pharmaceutical companies.

 

●    Sarcopenia (GF-1005):  We are making steady progress with our
project aimed at addressing mitochondrial dysfunction observed in sarcopenia.
This work focuses on restoring mitochondrial health as a key factor in
combating the condition. The loading of myoblast progenitors with centSIRT6 is
currently underway in collaboration with our partner, Université libre de
Bruxelles (ULB). We are optimistic that these efforts will pave the way for
innovative solutions to improve muscle health and combat sarcopenia
effectively.

 

Looking Ahead

 

As we prepare for 2025, we are energized by the progress we've made and the
opportunities ahead. Our commitment to tackling aging as a fundamental risk
factor for chronic diseases remains steadfast. With continued collaboration
and innovation, we are confident we will achieve great things in the coming
year.

 

Thank you all for your trust and support on this journey. Our stakeholders'
belief in what we're working towards means the world to us and we can't wait
to share more exciting updates in the months to come!

 

 

Dr Eric Leire

CEO

Genflow Biosciences Plc.

 

 

Contacts

 

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Brokers
 Capital Plus Partners Ltd

 Jon Critchley, +44 0203 821 6168

 

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction
Associated Steatohepatitis), the most prevalent chronic liver disease for
which there is no effective treatments. Please visit www.genflowbio.com and
follow the Company on LinkedIn and Twitter/X.

 

DISCLAIMER

 

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

 

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

 

Forward-looking statements include all matters that are not historical facts.
Forward looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

 

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFFLLVIVIIE